Ronald Blue & Co’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$3.82M Sell
46,416
-4,181
-8% -$341K 0.12% 30
2017
Q1
$4.26M Buy
50,597
+274
+0.5% +$21.9K 0.15% 28
2016
Q4
$3.7M Sell
50,323
-4,554
-8% -$339K 0.14% 28
2016
Q3
$4.4M Buy
54,877
+2,200
+4% +$176K 0.18% 23
2016
Q2
$4.15M Sell
52,677
-5,100
-9% -$384K 0.19% 20
2016
Q1
$4.16M Sell
57,777
-3,161
-5% -$239K 0.22% 18
2015
Q4
$5.13M Sell
60,938
-6,570
-10% -$545K 0.27% 22
2015
Q3
$5.65M Sell
67,508
-465
-0.7% -$39.3K 0.3% 13
2015
Q2
$5.67M Sell
67,973
-225
-0.3% -$17.1K 0.27% 17
2015
Q1
$4.96M Sell
68,198
-6,435
-9% -$458K 0.24% 19
2014
Q4
$5.15M Sell
74,633
-8,675
-10% -$586K 0.25% 18
2014
Q3
$5.4M Buy
83,308
+7,078
+9% +$448K 0.35% 12
2014
Q2
$4.74M Buy
76,230
+59
+0.1% +$3.52K 0.3% 13
2014
Q1
$4.48M Buy
76,171
+10,737
+16% +$599K 0.33% 12
2013
Q4
$3.34M Buy
65,434
+2,372
+4% +$119K 0.25% 23
2013
Q3
$3.17M Buy
63,062
+15,347
+32% +$803K 0.26% 21
2013
Q2
$2.34M Buy
+47,715
New +$2.6M 0.19% 18

Other funds holding LLY

Ronald Blue & Co's LLY Position: Q2 2017 in Review

Ronald Blue & Co reduced its Eli Lilly (LLY) stake by 8.3% in Q2 2017, selling an estimated $341K and leaving 46,416 shares worth $3.82M. The position accounts for 0.12% of the portfolio, ranked #30.

Ronald Blue & Co first reported a position in LLY in Q2 2013 and has held it in 17 quarters since. The position peaked at $5.67M in Q2 2015. 1,247 funds tracked by Wall St. Rank hold LLY as of Q2 2017.

  • Ronald Blue & Co held 46,416 shares of Eli Lilly worth $3.82M as of Q2 2017.
  • Ronald Blue & Co sold 4,181 Eli Lilly shares in Q2 2017, an estimated $341K.
  • Eli Lilly made up 0.12% of Ronald Blue & Co's portfolio in Q2 2017, its #30 holding.
  • Ronald Blue & Co first reported a position in Eli Lilly in Q2 2013 and has held it in 17 quarters since.
  • Ronald Blue & Co's Eli Lilly position peaked at $5.67M in Q2 2015.
  • 1,247 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2017.

Based on Ronald Blue & Co's 13F filing for Q2 2017, filed 28 Jul 2017.